Treatment of Breast Cancer Using Multistage Delivery of PI3K/mTOR Inhibitors

被引：0
|
作者：
Blanco, E.
Sangai, T.
Martinez, J. O.
Meric-Bernstam, F.
Ferrari, M.
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-14-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-14-10
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
    Bahrami, Afsane
    Khazaei, Majid
    Shahidsales, Soodabeh
    Hassanian, Seyed Mahdi
    Hasanzadeh, Malihe
    Maftouh, Mina
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (01) : 213 - 222
  • [22] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74
  • [23] PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
    Alzahrani, Ali S.
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 125 - 132
  • [24] Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment
    Condorelli, R.
    Andre, F.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1167 - 1168
  • [25] Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
    Yan, Chi
    Yang, Jinming
    Saleh, Nabil
    Chen, Sheau-Chiann
    Ayers, Gregory D.
    Abramson, Vandana G.
    Mayer, Ingrid A.
    Richmond, Ann
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
  • [26] Multistage delivery of RNA interfering nanotherapeutics targeting the PI3K/Akt/mTOR pathway
    Blanco, Elvin
    Wu, Suhong
    Cara, Francisca
    Segura-Ibarra, Victor
    Meric-Bernstam, Funda
    Ferrari, Mauro
    CANCER RESEARCH, 2015, 75
  • [27] Inhibitors of PI3Kβ as Potential Treatment for Cancer
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (09): : 815 - 816
  • [28] REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFIELDS) THROUGH ACTIVATION OF THE PI3K/AKT/MTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/MTOR DUAL INHIBITORS
    Klein-Goldberg, Anat
    Voloshin, Tali
    Zemer-Tov, Efrat
    Paz, Rom
    Koren, Lilach
    Wainer-Katsir, Kerem
    Volodin, Alexandra
    Koltun, Bella
    Brant, Boris
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2021, 23 : 84 - 84
  • [29] THE ROLE OF CDK AND PI3K/MTOR INHIBITORS
    Andre, Fabrice
    BREAST, 2015, 24 : S25 - S25
  • [30] PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
    Hao, Chunfang
    Wei, Yunchu
    Meng, Wenjing
    Zhang, Jie
    Yang, Xiaonan
    CANCER TREATMENT REVIEWS, 2025, 132
12345